Fundraising Fox

Summit Therapeutics

NASDAQ: SMMT

Miami, US · Founded 2020 · Delaware corporation

smmttx.com ↗

Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

BiotechHealthtech

Founders & leadership

MSManmeet Soni
Manmeet SoniExecutive
RD
Robert DugganExecutive
MZ
Mahkam ZanganehExecutive
DR
David RoblinExecutive
DW
David WurzerNamed on SEC filing
LZ
Leopoldo ZambelettiNamed on SEC filing
VA
Valerie AndrewsNamed on SEC filing
FA
Frank ArmstrongNamed on SEC filing
GE
Glyn EdwardsNamed on SEC filing
SD
Stephen DaviesNamed on SEC filing
JM
Jim MellonNamed on SEC filing
RS
Raymond SpencerNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$569M disclosed across 6 rounds · 2014–2024

▶$235MraisedSep 2024 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Manmeet SoniExecutive Officer, Director
  • Robert DugganExecutive Officer, Director
  • Jeff HuberDirector
  • Mahkam ZanganehExecutive Officer, Director
  • Mostafa RonaghiDirector
  • Alessandra CesanoDirector
  • Kenneth ClarkDirector
  • Yu XiaDirector
  • Robert BoothDirector
Offering amount
$235M
Amount sold
$235M
Proceeds to insiders
$75.5M
First sale
Sep 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yu XiaDirector
  • Ujwala MahatmeDirector
  • Manmeet SoniExecutive Officer, Director
  • Mostafa RonaghiDirector
  • Robert DugganExecutive Officer, Director
  • Mahkam ZanganehExecutive Officer, Director
  • Kenneth ClarkDirector
  • Alessandra CesanoDirector
  • Robert BoothDirector
Offering amount
$200M
Amount sold
$200M
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedNov 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert DugganExecutive Officer
  • Mahkam ZanganehDirector
  • Rainer ErdtmannDirector
  • Manmeet SoniDirector
  • Ujwala MahatmeDirector
  • Michael Paul DonaldsonExecutive Officer
  • Houbiers JosExecutive Officer
  • David Johnathan PowellExecutive Officer
  • Camilla GrahamExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Nov 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$47.4MraisedJan 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David RoblinExecutive Officer
  • Robert W. DugganDirector
  • Elaine StrackerDirector
  • Glyn EdwardsExecutive Officer, Director
  • Manmeet SoniDirector
  • Daniel ElgerExecutive Officer
  • Ventzislav StefanovDirector
Offering amount
$47.4M
Amount sold
$47.4M
First sale
Dec 2019
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David WurzerDirector
  • Leopoldo ZambelettiDirector
  • David RoblinExecutive Officer
  • Valerie AndrewsDirector
  • Frank ArmstrongDirector
  • Glyn EdwardsExecutive Officer, Director
Offering amount
$25M
Amount sold
$25M
First sale
Jan 2019
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.6MraisedMar 2014 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen DaviesDirector
  • Jim MellonDirector
  • Raymond SpencerExecutive Officer
  • Frank ArmstrongDirector
  • Glyn EdwardsExecutive Officer, Director
  • Barry PriceDirector
Offering amount
$11.6M
Amount sold
$11.6M
Sales commissions
$698.6K
Placement agents
JMP Securities LLC
First sale
Mar 2014
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Seeking Alpha82 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.

Companies competing with Summit Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Summit Therapeutics do?
Summit Therapeutics is a biopharmaceutical oncology company developing and commercializing cancer therapies, with a lead candidate, ivonescimab (SMT112/AK112), a bispecific antibody targeting PD-1 and VEGF currently in Phase 3 trials for non-small cell lung cancer. It licenses ivonescimab from Akeso for territories including the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
How much funding has Summit Therapeutics raised?
Summit Therapeutics has disclosed $569M raised across 6 rounds.
Where is Summit Therapeutics headquartered?
Summit Therapeutics is headquartered in Miami, US.